FOLD News and Press, Amicus Therapeutics Inc. From 03/01/23

2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and U.K. AT-GAA Regulatory Reviews On-Track; Approvals expected i...

Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce FY earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.79 (+14.1% Y/Y) and the consensus Revenue Estimate is $328.9M (+7.7% Y/Y). Over the last 1 year, FOLD has beaten E...

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T. A live audio webcast of the present...

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years Consistent Reduction in Biomarkers Continue to Suggest a Positive Effect on Muscle Tissue; Including Participants who Swit...

PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2022. Particip...

PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the 19th Annual WORLDSymposium™ 2023 , being held February 22-26, 2023 in Orlando, FL. ...

Summary Shares of plant-derived enzyme therapy concern Protalix BioTherapeutics, Inc. have rallied after its Fabry disease asset PLX-102 received a PDUFA date of May 9, 2023 from the FDA. The company is also anticipating a decision from the EMA on its application sometime in 1H23. W...

PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T. A live audio web...

Summary Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 2022. A good pipeline allows us to assume high growth in the coming years. ...

Summary AT-GAA's US approval is still held up by the China delay. Meanwhile, the company faces the risk of appearing overvalued. Impending IP challenges pose major risks. There is no further clarity on the delay of the NDA from Amicus Therapeutics ( FOLD ) for AT-GAA (...